• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vallon Pharmaceuticals Inc. (Amendment)

    2/13/23 4:30:59 PM ET
    $VLON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $VLON alert in real time by email
    SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     

     
    Vallon Pharmaceuticals, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.0001 per share
     
     
    (Title of Class of Securities)
     

     
    92023M101
     
     
    (CUSIP Number)
     

     
    December 31, 2022
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Fund II LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power

    7,500
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    7,500
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    7,500(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.1%
     
    12
    Type of Reporting Person (See Instructions)

    PN
     
    (1) The reporting person’s ownership consists of 7,500 common shares.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners II LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    7,500
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    7,500
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    7,500(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.1%
     
    12
    Type of Reporting Person (See Instructions)

    OO
     
    (1) The reporting person’s ownership consists of 7,500 common shares.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Macro Fund, LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power

    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.0%
     
    12
    Type of Reporting Person (See Instructions)

    PN
     



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power

    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.0%
     
    12
    Type of Reporting Person (See Instructions)

    PN
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    7,500
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    7,500
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    7,500(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.1%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of 7,500 common shares.


    Item 1.
     
    (a)
    Name of Issuer
       
     
    Vallon Pharmaceuticals, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    100 N. 18th Street, Suite 300
    Philadelphia, PA 19103

    Item 2.
     
    (a)
    Name of Person Filing
       
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •            Lind Global Fund II LP, a Delaware limited partnership;
    •            Lind Global Partners II LLC, a Delaware limited liability company;
    •            Lind Global Macro Fund LP, a Delaware limited partnership;
    •            Lind Global Partners LLC, a Delaware limited liability company; and
    •            Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Lind Global Partners LLC, the general partner of Lind Global Macro Fund, LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Macro Fund, LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC and Lind Global Partners LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP and Lind Global Macro Fund, LP.
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
     
    (c)
    Citizenship
       
     
    See Row 4 of cover page for each Reporting Person.
     
     
    (d)
    Title of Class of Securities
     
       
    Common Stock, par value $0.0001 per share
     


     
    (e)
    CUSIP Number
       
     
    92023M101

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.


    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1
    Joint Filing Agreement by and among the Reporting Persons


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 13, 2023
    LIND GLOBAL MACRO FUND, LP
     
       
    By:
    Lind Global Partners LLC
     
     
    its General Partner
     
         
    By:
    /s/ Jeff Easton
     
    Name:
    Jeff Easton
     
    Title:
    Managing Member
     
       
    LIND GLOBAL PARTNERS LLC
       
    By:
    /s/ Jeff Easton
    Name:
    Jeff Easton
    Title:
    Managing Member
       
    LIND GLOBAL FUND II LP
     
       
    By:
    Lind Global Partners II LLC
     
     
    its General Partner
     
         
    By:
    /s/ Jeff Easton
     
    Name:
    Jeff Easton
     
    Title:
    Managing Member
     
       
    LIND GLOBAL PARTNERS II LLC
       
    By:
    /s/ Jeff Easton
    Name:
    Jeff Easton
    Title:
    Managing Member
       
    JEFF EASTON
     
       
    By:
     
    /s/ Jeff Easton
     

    Get the next $VLON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VLON

    DatePrice TargetRatingAnalyst
    11/22/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VLON
    SEC Filings

    See more
    • SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.

      424B3 - GRI BIO, Inc. (0001824293) (Filer)

      2/2/24 4:25:45 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - GRI BIO, Inc. (0001824293) (Filer)

      2/2/24 4:23:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.

      424B4 - GRI BIO, Inc. (0001824293) (Filer)

      2/2/24 4:21:50 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Vallon Pharmaceuticals Inc.

      SC 13G - GRI BIO, Inc. (0001824293) (Subject)

      5/2/23 8:23:53 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Vallon Pharmaceuticals Inc.

      SC 13G - GRI BIO, Inc. (0001824293) (Subject)

      5/2/23 4:05:32 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Vallon Pharmaceuticals Inc.

      SC 13D - GRI BIO, Inc. (0001824293) (Subject)

      4/25/23 4:19:44 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Vallon Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Vallon Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      11/22/21 6:24:06 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

      Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T ("NKT") modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of the combined company into mid-2024 Trading on Nasdaq under the ticker symbol "GRI" expected to commence April 24, 2023 PHILADELPHIA, PA, April 21, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:VLON), ("GRI," "GRI Bio," or the "Company"), today announced the completion of the previously announced merger between Vallon Pharmaceuticals, Inc. (now GRI Bio, Inc.) and GRI Bio, Inc. (now GRI Bio Operations, Inc. and referred to herein as "Priva

      4/21/23 11:55:00 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

      Vallon's board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) ("Vallon" or the "Company") today announced that its stockholders have approved Proposals 1, 2, 4 and 5, related to the previously announced proposed merger with GRI Bio, Inc., a privately held biotechnology company ("GRI Bio" or "GRI"), at a special meeting of stockholders held on April 20, 2023 (the "Special Meeting"). Accordingly, at the effective time of the merger, each share of GRI's common stock, will be automatically converted into the right to receive a number of shares of Vallon's common st

      4/20/23 6:45:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

      Board of Directors unanimously recommend Vallon stockholders to vote "FOR" all proposals outlined in the Company's definitive Proxy Statement (the "Proxy") in order to close the proposed merger with GRI Bio, Inc. PHILADELPHIA, PA, April 12, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), today announced that its Special Meeting of Stockholders, scheduled for and convened on April 12, 2023, has been adjourned to provide the Company's stockholders additional time to consider and vote FOR the proposals in the Proxy. Vallon intends to reconvene the Special Meeting on April 20, 2023 at 9:00 am ET. The Vallon board of directors unanimou

      4/12/23 4:05:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Leadership Updates

    Live Leadership Updates

    See more
    • Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors

      Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies Philadelphia, PA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Meenu Karson to its Board of Directors. "We are excited to welcome Ms. Karson to our Board of Directors. Over the course of her career, she has l

      2/28/22 4:05:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

      - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the ~$9 billion US ADHD market PHILADELPHIA, PA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2021. The Company also provided an update on its development programs, ADAIR and ADMIR

      8/10/21 8:05:00 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer

      - Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e

      5/11/21 9:05:00 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kelly Leanne

      4 - GRI BIO, Inc. (0001824293) (Issuer)

      9/26/23 4:08:55 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Szekeres David Leslie

      4 - GRI BIO, Inc. (0001824293) (Issuer)

      8/14/23 4:10:06 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Simpson Camilla V

      4 - GRI BIO, Inc. (0001824293) (Issuer)

      8/14/23 4:07:42 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care